Statement - GlaxoSmithKline invests $12 Million in Canada for Influenza Research
"These investments are good for Canada and good for Canadians."
OTTAWA, - Rx&D President Russell Williams made the following statement today about GlaxoSmithKline plc's new funding of $12 Million to support an additional three-years of research to monitor seasonal influenza vaccine effectiveness in the elderly.
Read Full Article...
Welcome to CFP’s Comment Section!
The Comment section of online publications is the new front in the ongoing Cancel Culture Battle.
Big Tech and Big Media are gunning for the Conservative Voice—through their Comment Sections.
Canada Free Press wishes to stay in the fight, and we want our fans, followers, commenters there with us.
We ask only that commenters keep it civil, keep it clean.
Thank You for your patience and for staying aboard the CFP ‘Mother Ship’.
READ OUR Commenting Policy